Day: November 3, 2023

NORWOOD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”), (CSE: MRMD), (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that effective October 31, 2023, Susan M. Villare resigned as Chief Financial Officer of the Company. The Board of Directors has appointed Jon Levine, President and CEO, as the Company’s Interim Chief Financial Officer and has initiated a search process to identify and engage a new Chief Financial Officer. Additionally, the Company announced it will report third quarter 2023 financial results on November 8, 2023 after the markets close. Management will host a conference call on November 9, 2023 at 8:00 a.m. EST to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations...

Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023. The fireside chat is scheduled to take place on Monday, November 6, 2023, at 3:10 PM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition,...

XPENG P7 Wing Edition ExteriorXPENG P7 Wing Edition ExteriorXPENG P7 interiorXPENG P7 interiorAMSTERDAM, The Netherlands, Nov. 03, 2023 (GLOBE NEWSWIRE) — XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today shared the news that the international version of its all-electric sports sedan, XPENG P7, has received a Silver Nomination in Lyd & Billede Home’s Premium Electrical Car of the Year category for 2023/24. The new XPENG P7 has impressed Europe since its release and, on October 25, received a five-star safety rating in the 2023 Euro NCAP test thanks to its impressive body structure and comprehensive XPILOT Safety features. Lyd & Billede Home is the most significant media player in the Nordics in the consumer electronics...

Company has entered into a Heads of Terms with Unicarb® Activated Carbons, a product group of LSR Materials GmbH & Co KG (“LSR”), which specializes in the marketing of activated carbons and process carbons to address the growing European activated carbon opportunity GREENWOOD VILLAGE, Colo., Nov. 03, 2023 (GLOBE NEWSWIRE) — GlobeNewswire – Advanced Emissions Solutions, Inc. (NASDAQ: ADES) (the “Company” or “ADES”), an environmental technology company producing activated carbon and other unique carbon solutions for use in water, air and soil purification, sustainable energy, sustainable materials and energy transition applications, today announced that it has entered into a framework for a definitive supply agreement with LSR seeking to address the growing European markets for products related...

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as continued demand growth   Received U.S. Food and Drug Administration (FDA) approval for the expanded indication of ZORYVE in plaque psoriasis down to the age of 6 Substantially advanced our atopic dermatitis program with the supplemental New Drug Application (sNDA) submission, and positive read-outs from the INTEGUMENT-PED and long-term trials Appointed industry veterans Todd Edwards and John W. Smither as new Chief Commercial Officer and interim Chief Financial Officer, respectively Strengthened balance sheet with $100 million follow-on...

Reports third quarter 2023 total revenue of $6.1 million, representing growth of 30% compared to third quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2023. Recent HighlightsThird quarter total revenue (combined product and service revenue) increased 30% to $6.1 million Third quarter recurring revenue increased 17% to $3.4 million Placed five new Growth...

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations include the first review of primary endpoint results with longer follow-up from the pivotal trial for linvoseltamab in heavily pre-treated patients with multiple myeloma TARRYTOWN, N.Y., Nov. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA. These include research across six investigational medicines that span eight difficult-to-treat blood cancers and disorders. Together, these presentations showcase the diversity...

Dorel Juvenile maintains quarter-over-quarter earnings improvement. Dorel Home posts sequential improvement in results despite challenging consumer environment.MONTRÉAL, Nov. 03, 2023 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced results for the third quarter and nine months ended September 30, 2023. Third quarter revenue was US$359.7 million, down 3.9% from US$374.1 million last year. Reported and adjusted net loss1 from continuing operations was US$10.4 million or US$0.32 per diluted share, compared to US$36.7 million or US$1.13 per diluted share last year. Adjusted net loss1 from continuing operations was US$34.7 million or US$1.07 per diluted share last year. Nine-month revenue from continuing operations was US$1.038 billion, a decrease of 15.6% compared to US$1.230 billion last year. Reported...

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. “Morphic presented a comprehensive set of positive results from the 12-week induction phase of the EMERALD-1 study of MORF-057 in UC, showing consistent efficacy across-the-board...